Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/9421
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRakhimova M.B., Akhmedov K.S.-
dc.date.accessioned2023-11-26T15:51:14Z-
dc.date.available2023-11-26T15:51:14Z-
dc.date.issued2023-
dc.identifier.citationТошкентen_US
dc.identifier.issn2181-7812-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/9421-
dc.description.abstractCurrently, there is no doubt about the importance of the role of impaired endothelial functional state in the development of vascular pathology in a number of diseases, including rheumatic. With the advent and large-scale spread of a new coronavirus infection (COVID-19), a high rate of patient’s hospitalizations with ankylosing spondyloarthritis (AS) and the development of extrapulmonary complications, such as myocardial injuries, kidney damage and vascular thromboembolism, were noted. The development of this phenomenon confirms the connection with pronounced endothelial dysfunction and its damage. This article presents the results of evaluation of endothelial dysfunction in AS patients undergoing COVID-19.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesУДК;-
dc.subjectankylosing spondylitis, COVID-19, endothelial dysfunction.en_US
dc.titleEndothelin-1 as a biomarker of endothelial dysfunction in patients with ankylosing spondylitis after COVID-19en_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
47. ВЕСТНИК Axmedov X.S Raximova M.B.pdfEndothelin-1 as a biomarker of endothelial dysfunction in patients with ankylosing spondylitis after COVID-19797.62 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.